Pas de connexion internet — affichage de la version enregistrée de la page.

Verastem Inc

USUSD
← Vers le screener
US:VSTMLSE:0LOV

Verastem Inc (US:VSTM) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
verastem.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
Needham, United States
PDG
Robert Forrester
Employés
102
Fondée
2010
Actions en circulation
90.56 M au 2026-08-03
Flottant
70.57 M
Capitalisation boursière
697.34 M USD
Initiés
1.02%
Investisseurs institutionnels
110.92%
Secteur d'activité (SIC)
Pharmaceutical Preparations
ISIN
US92337C2035
LEI
549300IY0EFBIU8NQC81
Description

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksVSTM principaleUSD8.11 -1.88%actions ordinaires
LSE London Stock Exchange0LOV IOBUSD8.13 +0.00%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Aucun versement de dividendes n'a été trouvé (vérifié le 09.10.2026). L'entreprise ne verse probablement pas de dividendes.

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.10.15%9.19 M2026-06-30
Armistice Capital, LLC7.76%7.02 M2026-06-30
RTW Investments LP7.33%6.64 M2026-06-30
Deep Track Capital, Lp6.34%5.74 M2026-06-30
State Street Corporation5.67%5.13 M2026-06-30
Rosalind Advisors, Inc.4.4%3.99 M2026-06-30
Vanguard Capital Managem…4.25%3.85 M2026-06-30
Nantahala Capital Manage…3.96%3.58 M2026-06-30
SPDR SERIES TRUST-State…3.95%3.58 M2026-08-31
Stonepine Capital Manage…3.7%3.35 M2026-06-30
Vanguard Portfolio Manag…3.61%3.27 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.1%2.81 M2026-06-30
iShares Trust-iShares Ru…2.25%2.04 M2026-08-31
Vanguard Explorer Fund1.54%1.4 M2026-07-31
VANGUARD INDEX FUNDS-Van…1.06%960 5982026-06-30
Fidelity Salem Street Tr…0.96%872 7842026-07-31
Fidelity Covington Trust…0.88%793 3982026-08-31
iShares Trust-iShares Ru…0.83%755 8832026-08-31
BlackRock Funds-BlackRoc…0.77%701 3372026-05-31
PATERSON DANIEL W (Chief…≈0.65%589 9402026-08-03
VANGUARD HORIZON FUNDS-V…0.59%536 6512026-06-30
STUGLIK BRIAN M (Directo…≈0.15%137 1472026-05-21
CALKINS DANIEL (Chief Fi…≈0.13%118 0142026-09-21
BAILEY MICHAEL P (Direct…≈0.12%108 0002026-05-21
JOHNSON JOHN H. (Directo…≈0.06%52 6662026-05-21
KAPUR ANIL (Director)≈0.06%52 6662026-05-21
ROBERTSON MICHELLE (Dire…≈0.06%52 6662026-05-21
ROWINSKY ERIC K. (Direct…≈0.06%52 6662026-05-21
TOLLEFSON KARIN ANNA (Di…≈0.06%52 6662026-05-21
ROS MATTHEW (Chief Opera…≈0.06%50 0002025-04-01